NFE2L2 and metabolic dysfunction-associated steatohepatitis: While various recent studies have confirmed the beneficial role of NRF2 in NAFLD and NASH (34, 35, 36), there has also been a recent report suggesting that NRF2 activation in the liver does not lead to overall metabolic improvement but can cause liver pathology and systemic metabolic disturbances (37).